SUBSCRIBE
SUBSCRIBE
News   Drug Development

Gentium S.p.A. to Amend Primary Goal for Cancer Drug Defibrotide

November 5, 2007 | 
1 min read
Nov 5 (Reuters) - Gentium S.p.A. (GENT.O: Quote, Profile, Research) said it plans to amend the protocol for its late-stage trial of cancer drug Defibrotide with the main goal for the study to change from survival at 100 days to complete response.
Clinical research Phase 3
MORE ON THIS TOPIC
Halftone hand holding pen or stylus and writing on torn paper piece art collage banner template with copy space for text. Cut out shapes, hand gesture. Grunge modern retro vector illustration
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Close up shot of the dart arrow hit on bulleyes of dartboard to represent that the business reached the target with dark tone picture style. Target and goal as concept.
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
 · 
2 min read
 · 
Annalee Armstrong
Working man icon pushing the load on the line. Hard work, labor, effort and determination concept.
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
 · 
2 min read
 · 
Tristan Manalac